PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE

Journal of Lipid Research

Volumn 55, Issue 11, 2014, Pages 2370-2379

  Ason, Brandon ^a   Van Der Hoorn, José W A ^b   Chan, Joyce ^a   Lee, Edward ^a   Pieterman, Elsbet J ^b   Nguyen, Kathy Khanh ^a   Di, Mei ^a   Shetterly, Susan ^a   Tang, Jie ^a   Yeh, Wen Chen ^a   Schwarz, Margrit ^a   Jukema, J Wouter ^c   Scott, Rob ^a   Wasserman, Scott M ^a   Princen, Hans M G ^b   Jackson, Simon ^a  

^a AMGEN INC   (United States)

^b TNO   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti proprotein convertase subtilisin kexin type 9 antibody; Apolipoprotein E; Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ANTIBODY; APOLIPOPROTEIN E; CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 ANTIBODY; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL ESTER TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; FEMALE; LIPID ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BLOOD; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENE INACTIVATION; GENETICS; HUMAN; IMMUNOLOGY; LIVER; METABOLISM;

ANIMALS; ANTIBODIES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; LIVER; MICE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84912034516     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M053207     Document Type: Article

References (79)

1. Steinberg, D. 2004. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part I. J. Lipid Res. 45: 1583-1593.
2. Steinberg, D. 2005. The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res. 46: 179-190.
3. Maxfield, F. R., and I. Tabas. 2005. Role of cholesterol and lipid organization in disease. Nature. 438: 612-621.
4. Gylling, H. 2004. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int. J. Clin. Pract. 58: 859-866.
5. Top, B., B. P. Koeleman, J. A. Gevers Leuven, L. M. Havekes, and R. R. Frants. 1990. Rearrangements in the LDL receptor gene in Dutch familial hypercholesterolemic patients and the presence of a common 4 kb deletion. Atherosclerosis. 83: 127-136.
6. Hummel, M., Z. G. Li, D. Pfaffinger, L. Neven, and A. M. Scanu. 1990. Familial hypercholesterolemia in a rhesus monkey pedigree: molecular basis of low density lipoprotein receptor deficiency. Proc. Natl. Acad. Sci. USA. 87: 3122-3126.
7. Wilson, J. M., D. E. Johnston, D. M. Jefferson, and R. C. Mulligan. 1988. Correction of the genetic defect in hepatocytes from the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 85: 4421-4425.
8. Goldstein, J. L., and M. S. Brown. 2009. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29: 431-438.
9. Brown, M. S., and J. L. Goldstein. 2004. Lowering plasma cholesterol by raising ldl receptors. 1981. Atheroscler. Suppl. 5: 57-59.
10. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
11. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102: 5374-5379.
12. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116: 2995-3005.
13. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105: 1820-1825.
14. Zhang, D. W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282: 18602-18612.
15. Nguyen, M. A., T. Kosenko, and T. A. Lagace. 2014. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J. Lipid Res. 55: 266-275.
16. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
17. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
18. Du, F., Y. Hui, M. Zhang, M. F. Linton, S. Fazio, and D. Fan. 2011. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J. Biol. Chem. 286: 43054-43061.
19. Piper, D. E., S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, and N. P. Walker. 2007. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 15: 545-552.
20. Kotowski, I. K., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78: 410-422.
21. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
22. Naoumova, R. P., I. Tosi, D. Patel, C. Neuwirth, S. D. Horswell, A. D. Marais, C. van Heyningen, and A. K. Soutar. 2005. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler. Thromb. Vasc. Biol. 25: 2654-2660.
23. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
24. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, et al. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
25. Chan, J. C., D. E. Piper, Q. Cao, D. Liu, C. King, W. Wang, J. Tang, Q. Liu, J. Higbee, Z. Xia, et al. 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA. 106: 9820-9825.
26. Ni, Y. G., J. H. Condra, L. Orsatti, X. Shen, S. Di Marco, S. Pandit, M. J. Bottomley, L. Ruggeri, R. T. Cummings, R. M. Cubbon, et al. 2010. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285: 12882-12891.
27. Duff, C. J., M. J. Scott, I. T. Kirby, S. E. Hutchinson, S. L. Martin, and N. M. Hooper. 2009. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem. J. 419: 577-584.
28. Frank-Kamenetsky, M., A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA. 105: 11915-11920.
29. Liang, H., J. Chaparro-Riggers, P. Strop, T. Geng, J. E. Sutton, D. Tsai, L. Bai, Y. Abdiche, J. Dilley, J. Yu, et al. 2012. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther. 340: 228-236.
30. Stein, E. A., N. Honarpour, S. M. Wasserman, F. Xu, R. Scott, and F. J. Raal. 2013. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 128: 2113-2120.
31. Stein, E. A., D. Gipe, J. Bergeron, D. Gaudet, R. Weiss, R. Dufour, R. Wu, and R. Pordy. 2012. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 380: 29-36.
32. Giugliano, R. P., N. R. Desai, P. Kohli, W. J. Rogers, R. Somaratne, F. Huang, T. Liu, S. Mohanavelu, E. B. Hoffman, S. T. McDonald, et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 380: 2007-2017.
33. Sullivan, D., A. G. Olsson, R. Scott, J. B. Kim, A. Xue, V. Gebski, S. M. Wasserman, and E. A. Stein. 2012. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 308: 2497-2506.
34. Blom, D. J., T. Hala, M. Bolognese, M. J. Lillestol, P. D. Toth, L. Burgess, R. Ceska, E. Roth, M. J. Koren, C. M. Ballantyne, et al. 2014. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370: 1809-1819.
35. Robinson, J. G., B. S. Nedergaard, W. J. Rogers, J. Fialkow, J. M. Neutel, D. Ramstad, R. Somaratne, J. C. Legg, P. Nelson, R. Scott, et al. 2014. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 311: 1870-1882.
36. Hirayama, A., N. Honarpour, M. Yoshida, S. Yamashita, F. Huang, S. M. Wasserman, and T. Teramoto. 2014. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk. Circ. J. 78: 1073-1082.
37. Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., and Stein, E. A. (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 367, 1891-1900.
38. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
39. Fitzgerald, K., M. Frank-Kamenetsky, S. Shulga-Morskaya, A. Liebow, B. R. Bettencourt, J. E. Sutherland, R. M. Hutabarat, V. A. Clausen, V. Karsten, J. Cehelsky, et al. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 383: 60-68.
40. Stroes, E., D. Colquhoun, D. Sullivan, F. Civeira, R. S. Rosenson, G. F. Watts, E. Bruckert, L. Cho, R. Dent, B. Knusel, et al. 2014. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63: 2541-2548.
41. Koren, M. J., P. Lundqvist, M. Bolognese, J. M. Neutel, M. L. Monsalvo, J. Yang, J. B. Kim, R. Scott, S. M. Wasserman, and H. Bays. 2014. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63: 2531-2540.
42. Hooper, A. J., and J. R. Burnett. 2013. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin. Biol. Ther. 13: 429-435.
43. Awan, Z., H. Y. Choi, N. Stitziel, I. Ruel, M. A. Bamimore, R. Husa, M. H. Gagnon, R. H. Wang, G. M. Peloso, R. A. Hegele, et al. 2013. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 231: 218-222.
44. Marduel, M., K. Ouguerram, V. Serre, D. Bonnefont-Rousselot, A. Marques-Pinheiro, K. Erik Berge, M. Devillers, G. Luc, J. M. Lecerf, L. Tosolini, et al. 2013. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum. Mutat. 34: 83-87.
45. de Knijff, P., A. M. van den Maagdenberg, A. F. Stalenhoef, J. A. Leuven, P. N. Demacker, L. P. Kuyt, R. R. Frants, and L. M. Havekes. 1991. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J. Clin. Invest. 88: 643-655.
46. Smit, M., P. de Knijff, E. van der Kooij-Meijs, C. Groenendijk, A. M. van den Maagdenberg, J. A. Gevers Leuven, A. F. Stalenhoef, P. M. Stuyt, R. R. Frants, and L. M. Havekes. 1990. Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146 - gln) variant results in a dominant mode of inheritance. J. Lipid Res. 31: 45-53.
47. Denis, M., J. Marcinkiewicz, A. Zaid, D. Gauthier, S. Poirier, C. Lazure, N. G. Seidah, and A. Prat. 2012. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 125: 894-901.
48. van den Maagdenberg, A. M., M. H. Hofker, P. J. Krimpenfort, I. de Bruijn, B. van Vlijmen, H. van der Boom, L. M. Havekes, and R. R. Frants. 1993. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J. Biol. Chem. 268: 10540-10545.
49. Zadelaar, S., R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27: 1706-1721.
50. van der Hoogt, C. C., W. de Haan, M. Westerterp, M. Hoekstra, G. M. Dallinga-Thie, J. A. Romijn, H. M. Princen, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2007. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J. Lipid Res. 48: 1763-1771.
51. van der Hoorn, J. W., W. de Haan, J. F. Berbee, L. M. Havekes, J. W. Jukema, P. C. Rensen, and H. M. Princen. 2008. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE∗3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol. 28: 2016-2022.
52. de Haan, W., J. de Vries-van der Weij, J. W. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M. Princen, et al. 2008. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin. Circulation. 117: 2515-2522.
53. Westerterp, M., C. C. van der Hoogt, W. de Haan, E. H. Offerman, G. M. Dallinga-Thie, J. W. Jukema, L. M. Havekes, and P. C. Rensen. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE∗3-Leiden mice. Arterioscler. Thromb. Vasc. Biol. 26: 2552-2559.
54. Delsing, D. J., E. H. Offerman, W. van Duyvenvoorde, H. van Der Boom, E. C. de Wit, M. J. Gijbels, A. van Der Laarse, J. W. Jukema, L. M. Havekes, and H. M. Princen. 2001. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE∗3-Leiden mice. Circulation. 103: 1778-1786.
55. Kühnast, S., J. W. van der Hoorn, A. M. van den Hoek, L. M. Havekes, G. Liau, J. W. Jukema, and H. M. Princen. 2012. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE∗3Leiden.CETP transgenic mice with or without treatment with atorvastatin. J. Hypertens. 30: 107-116.
56. Stary, H. C., A. B. Chandler, R. E. Dinsmore, V. Fuster, S. Glagov, W. Insull, Jr., M. E. Rosenfeld, C. J. Schwartz, W. D. Wagner, and R. W. Wissler. 1995. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. 15: 1512-1531.
57. Fan, D., P. G. Yancey, S. Qiu, L. Ding, E. J. Weeber, M. F. Linton, and S. Fazio. 2008. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 47: 1631-1639.
58. Tavori, H., D. Fan, J. L. Blakemore, P. G. Yancey, L. Ding, M. F. Linton, and S. Fazio. 2013. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation. 127: 2403-2413.
59. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
60. van Dijk, K. W., M. H. Hofker, and L. M. Havekes. 1999. Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models. Curr. Atheroscler. Rep. 1: 101-107.
61. Ishibashi, S., J. Herz, N. Maeda, J. L. Goldstein, and M. S. Brown. 1994. The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc. Natl. Acad. Sci. USA. 91: 4431-4435.
62. Breslow, J. L. 1996. Mouse models of atherosclerosis. Science. 272: 685-688.
63. Sun, X. M., E. R. Eden, I. Tosi, C. K. Neuwirth, D. Wile, R. P. Naoumova, and A. K. Soutar. 2005. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum. Mol. Genet. 14: 1161-1169.
64. Herbert, B., D. Patel, S. N. Waddington, E. R. Eden, A. McAleenan, X. M. Sun, and A. K. Soutar. 2010. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler. Thromb. Vasc. Biol. 30: 1333-1339.
65. Roubtsova, A., M. N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, C. Lazure, K. Cianflone, N. G. Seidah, and A. Prat. 2011. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31: 785-791.
66. Poirier, S., G. Mayer, S. Benjannet, E. Bergeron, J. Marcinkiewicz, N. Nassoury, H. Mayer, J. Nimpf, A. Prat, and N. G. Seidah. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283: 2363-2372.
67. Canuel, M., X. Sun, M. C. Asselin, E. Paramithiotis, A. Prat, and N. G. Seidah. 2013. Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE. 8: e64145.
68. Espirito Santo, S. M., P. C. Rensen, J. R. Goudriaan, A. Bensadoun, N. Bovenschen, P. J. Voshol, L. M. Havekes, and B. J. van Vlijmen. 2005. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J. Lipid Res. 46: 1097-1102.
69. Le May, C., J. M. Berger, A. Lespine, B. Pillot, X. Prieur, E. Letessier, M. M. Hussain, X. Collet, B. Cariou, and P. Costet. 2013. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 33: 1484-1493.
70. Mortimer, B. C., D. J. Beveridge, I. J. Martins, and T. G. Redgrave. 1995. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J. Biol. Chem. 270: 28767-28776.
71. Ishibashi, S., S. Perrey, Z. Chen, J. Osuga, M. Shimada, K. Ohashi, K. Harada, Y. Yazaki, and N. Yamada. 1996. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271: 22422-22427.
72. van der Hoorn, J. W., R. Kleemann, L. M. Havekes, T. Kooistra, H. M. Princen, and J. W. Jukema. 2007. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE∗3Leiden transgenic mice. J. Hypertens. 25: 2454-2462.
73. Kooistra, T., L. Verschuren, J. de Vries-van der Weij, W. Koenig, K. Toet, H. M. Princen, and R. Kleemann. 2006. Fenofibrate reduces atherogenesis in ApoE∗3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler. Thromb. Vasc. Biol. 26: 2322-2330.
74. Kleemann, R., H. M. Princen, J. J. Emeis, J. W. Jukema, R. D. Fontijn, A. J. Horrevoets, T. Kooistra, and L. M. Havekes. 2003. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE∗3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 108: 1368-1374.
75. Jiang, X. C., L. B. Agellon, A. Walsh, J. L. Breslow, and A. Tall. 1992. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J. Clin. Invest. 90: 1290-1295.
76. van den Hoek, A. M., J. W. van der Hoorn, A. C. Maas, R. M. van den Hoogen, A. van Nieuwkoop, S. Droog, E. H. Offerman, E. J. Pieterman, L. M. Havekes, and H. M. Princen. 2014. APOE∗3Leiden. CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes Obes. Metab. 16: 537-544.
77. Ferri, N., G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, and A. L. Catapano. 2012. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 220: 381-386.
78. Shen, L., H. C. Peng, S. N. Nees, S. P. Zhao, and D. Y. Xu. 2013. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport. FEBS Lett. 587: 1271-1274.
79. Baigent, C., L. Blackwell, J. Emberson, L. E. Holland, C. Reith, N. Bhala, R. Peto, E. H. Barnes, A. Keech, J. Simes, et al. 2010. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 1670-1681.